·SEC EDGARLow
LAUCK ANDREW purchased $10K of SRTA
LAUCK ANDREW purchased 2,000 shares of Strata Critical Medical, Inc. (SRTA) at $5.00 on 2026-11-05.
StockNASDAQ · US · USDHealthcare · MEDICAL CARE FACILITIES
$SRTA
Strata Critical Medical, Inc.
Strata Critical Medical provides time-critical logistics and medical services to the U.S. healthcare industry, serving transplant centers, organ procurement organizations, hospitals and other businesses. Its Logistics segment, marketed under the Trinity brand, arranges air and ground transport for organs and related personnel and materials, coordinates organ placement through Trinity Organ Placement Services (TOPS), and supports the transplant process. Its Clinical segment, marketed under the Keystone brand, provides organ recovery surgery, normothermic regional perfusion and preservation, as well as cardiac perfusion, blood management, autotransfusion, ECMO, temporary staffing and equipment rental. Strata makes money through contractual and per-case fees, including fixed hourly pricing for air logistics, monthly fees for TOPS, and retainers and per-case charges for clinical services. It also leases perfusion equipment. The company uses third-party aircraft operators, owned vehicles and third-party ground providers to deliver logistics services. Its employees are located across the United States.
AlphAI earnings readQ3 FY2026 · NOV 3Strata Critical Medical Announces Third Quarter 2026 ResultsVerdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $SRTAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $SRTA in the last 7 days.
Insider · 30dAll trades →
- Buys
- $10K 1 txs
- Sells
- — 0 txs
LAUCK ANDREW1× · $10K
10b5-1 share of filings0%
Top stories · $SRTAMore →
·finance.yahoo.com
Strata Critical Medical Q3 Earnings Call Highlights
Strata Critical Medical (SRTA) reported Q3 clinical gross profit up 18.3% sequentially, but gross margin declined to 25.6%. Logistics revenue fell 6.9% sequentially, while gross margin improved to 20.8%. The company expects higher margins in 2027. Strata ended the quarter with $41.6M in cash and authorized a $20M share repurchase. It reiterated 2026 guidance and expects high-teens organic adjusted EBITDA growth in 2027.
·SEC EDGAR 8-K
Strata Critical Medical Announces Third Quarter 2026 Results
Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 November 3, 2026 Strata Critical Medical Announces Third Quarter 2026 Results • Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 • Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 • Q3 2026 net loss from continuing operations of $
SRTA sentiment & insider activity
Recent SRTA coverage spans earnings, insider activity and mergers & acquisitions.
In the last 30 days, SRTA insiders filed 1 SEC Form 4 transaction — 1 purchase ($10K) and no sales. The most active reporter was LAUCK ANDREW with 1 filing.
What's driving SRTA
Small insider purchase may signal confidence but size is negligible for price.
Margin dynamics and reiterated guidance, plus a new buyback authorization, likely support the stock while investors watch 2027 margin recovery and logistics stabilization.
Strong top-line growth and cash generation suggest positive earnings momentum.
The upcoming earnings release may drive short-term price movement as traders position ahead of the report.
Activist ownership plus an explicit sale push can raise takeover odds and compress the probability-weighted downside, supporting near-term sentiment.
AlphAI scores every news story that mentions SRTA with an AI model for sentiment and relevance, and aggregates insider trades from Strata Critical Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $SRTA
Score
LAUCK ANDREW purchased $10K of SRTA
LAUCK ANDREW purchased 2,000 shares of Strata Critical Medical, Inc. (SRTA) at $5.00 on 2026-11-05.
Strata Critical Medical Q3 Earnings Call Highlights
Strata Critical Medical (SRTA) reported Q3 clinical gross profit up 18.3% sequentially, but gross margin declined to 25.6%. Logistics revenue fell 6.9% sequentially, while gross margin improved to 20.8%. The company expects higher margins in 2027. Strata ended the quarter with $41.6M in cash and authorized a $20M share repurchase. It reiterated 2026 guidance and expects high-teens organic adjusted EBITDA growth in 2027.
Strata Critical Medical Announces Third Quarter 2026 Results
Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 November 3, 2026 Strata Critical Medical Announces Third Quarter 2026 Results • Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 • Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 • Q3 2026 net loss from continuing operations of $
Third-quarter results will be released before markets open Nov. 3; Strata's call starts at 8 a.m.
Strata Critical Medical (SRTA) will release Q3 2026 results on Nov. 3 before market open. A conference call at 8 a.m. ET will discuss results, hosted by CEOs Melissa Tomkiel and Will Heyburn. The call will include a Q&A session and be webcast on the company's investor relations page.
Strata Critical Medical gains as activist Third Point takes stake, pushes for sale
Strata Critical Medical (SRTA) shares rose 5.3% after Third Point disclosed a 5.8% stake and urged a sale. Third Point is now the company's third-largest shareholder.
Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript
Strata Critical Medical (SRTA) reported Q2 2026 results, citing 15.1% sequential organic clinical revenue growth, with Transplant Clinical up 23.8%. Clinical gross margin rose to 26.1%. It generated $5.7M operating cash flow and $2.9M free cash flow. The company completed three bolt-on acquisitions and expects stronger cash generation in H2.
Strata Critical Medical Announces Second Quarter 2026 Results
Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clini
Cathie Wood Goes On A Massive Shopping Spree: Ark Adds Tesla, Palantir, Cerebras, Amazon And Alphabet To
Ark Invest, led by Cathie Wood, reported major trades on Tuesday: it added Tesla, Palantir, Cerebras (25,795 shares for about $5.8M at $226.72), Alphabet GOOG (23,603 Class C shares for about $8.2M at $346.08), and CoreWeave (76,195 shares for about $8.1M at $105.72). It also sold Roku and Strata Critical Medical. Tesla faces scrutiny over FSD after a Texas crash, according to the article.
Heyburn William A. sold $186K of SRTA
Heyburn William A. (Co-CEO and CFO) sold 31,671 shares of Strata Critical Medical, Inc. (SRTA) at $5.87 ($0.19M total) on 2026-06-08.
Tomkiel Melissa M. sold $175K of SRTA
Tomkiel Melissa M. (Co-CEO and General Counsel) sold 29,730 shares of Strata Critical Medical, Inc. (SRTA) at $5.87 ($0.17M total) on 2026-06-08.